BullFrog AI Holdings, Inc. uses artificial intelligence and machine learning to turn complex biomedical data into actionable insights for drug discovery and development. Company news centers on the bfLEAP® platform, data harmonization through bfPREP™, and bfARENAS™, a scenario-based decision engine for pharmaceutical portfolio strategy, target selection, biomarker strategy and clinical trial design.
Recurring updates also cover commercial feasibility agreements with pharmaceutical customers, research-institution collaborations, white papers and conference participation in life sciences and oncology. Corporate news includes Nasdaq continued-listing compliance, at-the-market and equity-line financing activity, balance-sheet updates, and shareholder communications tied to the company’s common stock and tradable warrants.
BullFrog AI (BFRG) announced that founder and CEO Vin Singh will deliver the keynote at the AI Drug Discovery & Development Summit. The presentation, titled “AI Drug Discovery: How Far We've Come,” is scheduled for October 27, 2026, at 5:30 p.m. Eastern Time in Boston. Singh will discuss AI's progress in drug discovery, early clinical findings across the industry and challenges in later-stage development. He will also explore how discovery efficiencies translate into overall development costs, clinical success rates and patient outcomes.
BullFrog AI Holdings (BFRG) will present to investors at the 20th Annual LD Micro Main Event on October 20, 2026.
Founder and CEO Vin Singh is scheduled to speak at 12:30 p.m. PT. The conference runs October 19–21 at the Luxe Sunset Boulevard Hotel in Los Angeles. Singh will also be available for one-on-one institutional investor meetings. A live webcast and replay will be publicly accessible through the company’s Investor Relations website.
BullFrog AI (BFRG) achieved project milestones in its commercial drug discovery program with a top 5 global pharmaceutical company. Its AI platform identified and prioritized novel therapeutic targets for major depressive disorder using proprietary biomedical datasets. The company views its first commercial project with a global pharmaceutical company as commercial-scale validation of its technology.
BullFrog AI (BFRG) will participate in two virtual investor conferences in September 2026.
At the iAccess Alpha Virtual Best Ideas Fall Investment Conference on September 15–16, CEO Vin Singh will present at 2:00 PM ET on September 15 and hold one-on-one meetings with institutional investors on September 16. At the Water Tower Research Insights Conference on September 22–23, a fireside chat with CEO Vin Singh, led by James Kisner of Water Tower Research, is scheduled for 1:00 PM ET on September 23.
Live webcasts for both events will be accessible via the Investors section of BullFrog AI’s website, with replays archived under the Company’s News & Events page. Additional registration and meeting details are available on the respective conference websites.
BullFrog AI (NASDAQ: BFRG)/b) announced that its management team will participate in the , held July 28-29, 2026. The event gathers established and emerging healthcare companies for one-on-one investor meetings and thematic panel discussions.
BullFrog AI management will join one-on-one investor meetings on Wednesday, July 29, 2026. Investors interested in scheduling a meeting are advised to contact their BTIG representative.
BullFrog AI (NASDAQ: BFRG) announced that Founder and CEO Vin Singh will participate in the Water Tower Research Fireside Chat Series on Thursday, July 23, 2026, at 1:00 pm ET. The open-access event will discuss BullFrog AI’s value proposition, causal AI platform, first pharma agreement, commercial strategy, business model, and upcoming milestones. Investors can register via Water Tower Research or BullFrog AI’s investor relations website.
BullFrog AI (NASDAQ:BFRG) appointed a new commercial leadership team to support its growth strategy for its integrated pharmaceutical AI platform, including bfPREP, bfLEAP and bfARENAS.
New leaders John Stewart, Eric Roos and Tom Hazel will focus on commercial sales, business development, corporate strategy and scientific operations to strengthen the company’s global commercial pipeline.
BullFrog AI (NASDAQ: BFRG) regained compliance with Nasdaq Listing Rule 5550(b)(1) by restoring minimum stockholders’ equity of $2,500,000 as of April 21, 2026. Compliance was achieved through sales under its at-the-market facility and an equity line of credit, extending cash runway into late 2027.
The company will be subject to a mandatory Nasdaq panel monitor for one year beginning April 21, 2026; a repeat noncompliance during that period could lead to prompt delisting procedures but allows a hearing request.
BullFrog AI (NASDAQ: BFRG) will exhibit at the American Association for Cancer Research Annual Meeting 2026 in San Diego from April 17-22, showcasing its end-to-end AI-driven drug discovery and development workflow at booth 2957.
Company representatives will be available for meetings and inquiries; contact Steven Seegers for scheduling.
BullFrog AI (Nasdaq: BFRG) announced a commercial feasibility agreement with a top 5 global pharmaceutical company on March 30, 2026 to identify drug targets for major depressive disorder using its bfLEAP® platform. The company raised financing that it says secures runway into late 2027 and launched bfARENAS™ to complete its end-to-end AI stack.